Afrezza 8 Unit (90)- 12 Unit (90)

Uses

Insulin Aspart is an insulin analog used to improve glycemic control in adults and children with diabetes mellitus

Dosage

Afrezza 8 Unit (90)- 12 Unit (90) dosage

The dosage of insulin aspart must be individualized.

Subcutaneous injection: insulin aspart should generally be given immediately (within 5-10 minutes) prior to the start of a meal.

Use in pumps: Change the insulin aspart in the reservoir at least every 6 days, change the infusion set, and the infusion set insertion site at least every 3 days. insulin aspart should not be mixed with other insulins or with a diluent when it is used in the pump.

Intravenous use: insulin aspart should be used at concentrations from 0.05 U/mL to 1.0 U/mL insulin aspart in infusion systems using polypropylene infusion bags. insulin aspart has been shown to be stable in infusion fluids such as 0.9% sodiumchloride.

Side Effects

Adverse events commonly associated with human insulin therapy include the following: Allergic reactions. Injection site reaction, lipodystrophy, pruritus, rash, lipoatrophy, hypokalaemia, blurred vision. Hypoglycaemia, insulin resistance.

Precaution

Pregnancy (insulin requirements tend to fall during the 1 st trimester, increase during the 2nd and 3rd) and lactation. Regular monitoring of HbAlc and blood glucose concentrations. Caution with increased insulin requirements: Fever, hyperthyroidism, trauma, infection, surgery

Interaction

Reduce insulin requirements with oral hypoglycemics, octreotide, MAOIs, ACE inhibitors, salicylates, alcohol, anabolic steroids & sulfonamides; increase insulin requirements with OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics & danazol. Alcohol may intensify & prolong the glucose lowering effect of insulin.

Pregnancy & Breastfeeding use

Pregnancy Category-B. Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation: Unknown whether distributed in breast milk; compatible with breast feeding, but lactating women may require dosage adjustment; caution advised

Contraindication

Do not use during episodes of hypoglycemia. Do not use in patients with hypersensitivity to NovoLog or one of its excipients.

Special Warning

Pediatric: Has not been studied in children with type 2 diabetes. Has not been studied in children with type 1 diabetes <2 years of age

Storage Condition

Unused Insulin Aspart should be stored in a refrigerator between 2° and 8°C. Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze Insulin Aspart and do not use Insulin Aspart if it has been frozen. Insulin Aspart should not be drawn into a syringe and stored for later use.

Vials: After initial use a vial may be kept at temperatures below 30°C for up to 28 days, but should not be exposed to excessive heat or sunlight. Opened vials may be refrigerated.

Innovators Monograph

You find simplified version here Afrezza 8 Unit (90)- 12 Unit (90)